A Phase 1 and Biodistribution Study of ABT-806i, an


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 08 07 2020
accepted: 16 09 2020
pubmed: 30 1 2021
medline: 27 8 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of

Identifiants

pubmed: 33509972
pii: jnumed.120.253146
doi: 10.2967/jnumed.120.253146
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Immunoconjugates 0
Indium Radioisotopes 0
Indium-111 E9NGC49E0T
ErbB Receptors EC 2.7.10.1
depatuxizumab W984C353CG

Banques de données

ClinicalTrials.gov
['NCT01472003']

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

787-794

Informations de copyright

© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Hui K Gan (HK)

Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia hui.gan@onjcri.org.au.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Department of Medicine, University of Melbourne, Melbourne, Australia.

Matthew Burge (M)

Royal Brisbane and Women's Hospital, Brisbane, Australia.
University of Queensland, Brisbane, Australia.

Benjamin Solomon (B)

Department of Medicine, University of Melbourne, Melbourne, Australia.
Peter MacCallum Cancer Centre, Melbourne, Australia.

Sze Ting Lee (ST)

Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.

Kyle D Holen (KD)

AbbVie, North Chicago, Illinois; and.

Yumin Zhang (Y)

Sinotau Pharmaceutical Group, Beijing, China.

Marika Ciprotti (M)

Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.

F T Lee (FT)

Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.

Wijith Munasinghe (W)

AbbVie, North Chicago, Illinois; and.

JuDee Fischer (J)

AbbVie, North Chicago, Illinois; and.

Peter Ansell (P)

AbbVie, North Chicago, Illinois; and.

Gerard Fox (G)

AbbVie, North Chicago, Illinois; and.

Hao Xiong (H)

AbbVie, North Chicago, Illinois; and.

Edward B Reilly (EB)

AbbVie, North Chicago, Illinois; and.

Rod Humerickhouse (R)

AbbVie, North Chicago, Illinois; and.

Andrew M Scott (AM)

Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Department of Medicine, University of Melbourne, Melbourne, Australia.
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH